1. Home
  2. EQH vs KTTA Comparison

EQH vs KTTA Comparison

Compare EQH & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EQH
  • KTTA
  • Stock Information
  • Founded
  • EQH 1859
  • KTTA 2020
  • Country
  • EQH United States
  • KTTA United States
  • Employees
  • EQH N/A
  • KTTA N/A
  • Industry
  • EQH Specialty Insurers
  • KTTA Biotechnology: Pharmaceutical Preparations
  • Sector
  • EQH Finance
  • KTTA Health Care
  • Exchange
  • EQH Nasdaq
  • KTTA Nasdaq
  • Market Cap
  • EQH N/A
  • KTTA 5.5M
  • IPO Year
  • EQH N/A
  • KTTA 2021
  • Fundamental
  • Price
  • EQH $54.80
  • KTTA $0.71
  • Analyst Decision
  • EQH Strong Buy
  • KTTA
  • Analyst Count
  • EQH 10
  • KTTA 0
  • Target Price
  • EQH $64.60
  • KTTA N/A
  • AVG Volume (30 Days)
  • EQH 2.7M
  • KTTA 152.0K
  • Earning Date
  • EQH 08-05-2025
  • KTTA 08-12-2025
  • Dividend Yield
  • EQH 1.96%
  • KTTA N/A
  • EPS Growth
  • EQH 13.70
  • KTTA N/A
  • EPS
  • EQH 3.76
  • KTTA N/A
  • Revenue
  • EQH $15,105,000,000.00
  • KTTA N/A
  • Revenue This Year
  • EQH $22.89
  • KTTA N/A
  • Revenue Next Year
  • EQH $3.86
  • KTTA N/A
  • P/E Ratio
  • EQH $14.63
  • KTTA N/A
  • Revenue Growth
  • EQH 45.39
  • KTTA N/A
  • 52 Week Low
  • EQH $36.46
  • KTTA $0.70
  • 52 Week High
  • EQH $56.61
  • KTTA $7.50
  • Technical
  • Relative Strength Index (RSI)
  • EQH 54.21
  • KTTA 34.09
  • Support Level
  • EQH $54.39
  • KTTA $0.70
  • Resistance Level
  • EQH $56.42
  • KTTA $0.77
  • Average True Range (ATR)
  • EQH 1.12
  • KTTA 0.04
  • MACD
  • EQH -0.06
  • KTTA 0.01
  • Stochastic Oscillator
  • EQH 62.81
  • KTTA 5.10

About KTTA Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).

Share on Social Networks: